SUMMARY This report presents an analysis of the cumulative survival in 110 well defined patients with systemic lupus erythematosus (SLE) who were followed up over a prolonged period of time. Special attention was paid to possible differences between patients who died and those who were still alive at the end of the study. Of the 110 patients with SLE, 96 (87%) were still alive after 10 years; the cumulative survival for men was 69% (11/16) and for women 90% (85/94). Patients who never developed a new exacerbation after the diagnosis for SLE had been established had a 10 year survival of 100%; for patients with one, two, or three exacerbations the 10 year survival was 91%, 69%, and 33% respectively. From these prospective studies it was found that the exacerbation frequency is most closely related to survival. Disease symptoms of renal involvement or neurological involvement, or both, present at the onset or at the moment the SLE diagnosis was established, were predominantly seen in patients who died during the follow up.
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In the past three decades the general'concept of the disease course of systemic lupus erythematosus (SLE) has changed dramatically. The old view, of a relatively unremitting disease course ending with death in a few years in most patients, has gradually been replaced by a new one, in which remission to some degree occurs in most patients and 50% or more are still alive after five years of follow up. [1] [2] [3] Albert et al in 1979 noted that survival as well as average disease duration until death both increased in a linear fashion related to the date of publication of papers devoted to this subject, without an apparent change in the slope of the curve in the mid1950s, when high dose steroid treatment became widely applied. This suggests that the improved survival rate was not related to the employed dose of prednisone but rather to other factors-for example, to the use of antihypertensive drugs, antibiotics, haemodialysis, and also to the establishment of well defined criteria for diagnosis5 6and the development of a variety of assays for the detection of antinuclear antibodies. It has often been stated that in recent years less severely ill patients are better recognised and reported than in the past.6 7 Also, according to the revised American Rheumatism Association (ARA) criteria, skin involvement only (malar rash, discoid rash, photosensitivity, oral ulcers) is sufficient for the diagnosis SLE.
To estimate the prognosis of the disease the life duration of patients with SLE can be measured starting from the date of a verified diagnosis or, less well defined, from the date of appearance of the first physical evidence of illness possibly attributable to SLE. Until now most studies of the survival of patients with SLE have been carried out retrospectively rather than prospectively.8 Most studies started with a group of patients who were sufficiently ill to seek hospital treatment and in whom SLE was diagnosed based on clinical and laboratory tests.
To study the survival of patients with SLE, 447 however, one should begin with subjects who are clinically well, rather than ill, and trace developments in them from health to illness and, if possible, to eventual death. Prolonged periodic observation permits events to be recorded and dated on the basis of objective observations made by the physician rather than on the retrospective and often subjective memory of the patient.
In 1970 a department was started at the central laboratory of the Red Cross blood transfusion service to develop methods for the detection of antinuclear antibodies. Soon it became necessary to establish the clinical significance of the various antinuclear antibodies. Therefore, three special lupus outpatient clinics were established in the Netherlands. From that time on patients were sent to these outpatient clinics for confirmation of the possible diagnosis of SLE and for treatment.
At that time different prospective studies were started to elucidate the diagnostic significance of anti-double-stranded DNA (anti-dsDNA),9 the prognostic significance of anti-dsDNA,10
" and the role of the complement system in the pathogenesis of SLE.1 12 From all patients sent to our lupus outpatient clinics, clinical data were recorded using well defined protocols. This allows us now to evaluate prospectively the history or disease course of a large group of patients who developed or had already developed SLE when they were first seen at one of our outpatient clinics. The aim of this study was to analyse survival in a group of well defined patients with SLE who were followed up over a long period of time, focusing on differences between patients who died and patients who were still alive at the end of our study. Attention was paid to differences in sex, age, age of onset of disease and the interval between onset and time of diagnosis (ARA criteria), number of ARA criteria fulfilled, and the amount and kind of exacerbations. Most, but not all, previously cited criticisms about the determination of survival in patients with SLE have been overcome by the prospective nature of this study, and this has enabled us to obtain an insight into the survival of patients with SLE defined according to ARA criteria.
Patients and methods

PATIENTS
All patients who fulfilled ARA criteria5 for SLE and who had been seen and followed up at one of our outpatient clinics since 1970 were incorporated in the study. Initially, these patients were seen at our department for diagnostic reasons. From their disease history we established a date of disease onset. Time periods between disease onset and establishment of the diagnosis SLE were quite variable. Only patients whose final diagnosis was SLE were incorporated in the study. Thus we followed up 110 patients in the years preceding 1987. Fourteen of these patients died during the study. Table 1 shows the demographic features of these 110 patients.
DIAGNOSIS
From the start of our study in 1970 until the end in 1986 the preliminary ARA criteria were used to diagnose SLE.s Use of the revised criteria (1982)6 did not change the data on the onset of SLE in our patients. Onset of disease was defined as the date on which the patient had complaints related to SLE for the first time.
DISEASE ACTIVITY
Disease activity of patients with SLE can be divided into minor and major symptoms, as previously described.'0 13Minor symptoms are mainly restricted to the musculoskeletal system and the skin and may be controlled by an increase of prednisolone dosage of 5-15 mg/day without the need for admission 'to hospital.
Major symptoms are characterised by at least one of the following manifestations: renal impairment, serositis, anaemia (haemoglobin<110 g/l) or leucopenia (white blood cell count<4x 109/l or thrombocytopenia (platelet count<50x 109/l), neurological, or psychiatric symptoms. All cases in which the symptoms were explained by causes other than SLE were excluded. Patients with pre-established renal involvement were considered to be inactive when no significant alterations took place in the creatinine values, proteinuria, urine sediment, or blood pressure. Renal function was assumed to have deteriorated when one or more of the following occurred on at least three consecutive days: increase of protein to at least 1 g/24 h, increase in red blood cell count in the urinary sediment, decrease in glomerular filtration rate of more than 20%. An increase in proteinuria or other indications of a Table 2 shows the general differences between the patients who died during the study (group II) and those who survived (group I). Several significant differences between these two groups were noted. Firstly, the male/female ratio of patients who died during the investigation was higher than that of patients who survived (0.56 v 0.13). Secondly, the exacerbation frequency of patients who died was Onset to diagnosis 4-6 (6-6) 10-1 (11-6) Diagnosis to end of the study 7,7 (4-9)
General differences
8-4 (6-0) *There was no statistical significance between groups I and II.
higher than that of patients who survived (100% of the patients who died had one or more exacerbations of the disease as compared with 50% of the patients still living at the end of the study). Furthermore, the time between onset of disease and diagnosis was longer for patients who died than for those who survived (10.1 years v 4*6 years).
No differences were found between male and female patients who died during the disease course. The men, however, tended to be older than the women at the onset of the disease and also at death (Tables 3 and 4) . Table 4 summarises the causes of death in the patients with SLE. A 'natural' cause of death was observed in 'only' three patients. In the other patients a direct link between the disease course and death could be found.
Clinical picture at the onset and time of diagnosis of SLE of those who died and those who survived We took into account a number of clinical symptoms closely related to the ARA criteria and attempted to discover whether there were differences between the patients who died (group II) and those who Age at death (mean (SD)) 59 (7.9) 43 (22) survived (group I). Differences between the amount and kind of exacerbations Table 2 shows that exacerbations occurred in 50% of the surviving patients and in 100% of the patients who died. Figure 1 compares both groups according to the occurrence and frequency of subsequent exacerbations. Clearly, the percentage of patients having an exacerbation was greater in group II than in group I. The frequency of exacerbations was also higher. In 25% of all men and 47% of all women investigated no exacerbation had been registered by the end of the study. The question of differences in the kind of exacerbation exists. Because the numbers of patients with more than one exacerbation were quite small only clinical differences between the two groups regarding the first exacerbation have been evaluated. Table 6 shows the prevalence of the clinical symptoms evaluated for group I (surviving) and group II (dead) patients. Neurological involvement was significantly increased in group II. Symptoms of renal involvement were also found twice as often in the patients who died than in those surviving. The fact that pleuritis was never found in the second patient group is remarkable; this is in contrast with signs of pericarditis.
SURVIVAL
At the end of this study 14 patients had died. Different methods of survival calculation can be followed. Figure 2A shows a cumulative index related to the follow up duration of all patients.
When the patients were divided into groups developing no exacerbation or one or more exacerbation we found that survival rates changed significantly, being more favourable for patients who after diagnosis of SLE had no subsequent exacerbation (Fig. 2B) . Figure 2C illustrates the differences between the survival rates of men and women.
For all 110 patients with SLE a 10 year cumulative survival of 87% was calculated. For the male patients with SLE this percentage was 69%, in contrast with 90% for the female patients. Differ- SLE as a point of entry must-in our view-be avoided as the first symptoms can be perceived and interpreted differently by individual patients. In this study nearly all patients could be followed up from date of onset; nevertheless, in estimating the survival we used the date of diagnosis, defined by the fulfilment of four or more of the preliminary ARA criteria. The time lapse between date of onset and date of diagnosis varied from less than one month to 12 years (mean (SD) 7 (8.5) years).
In our study a prognosis is estimated for patients presenting to our lupus outpatient clinics. Prognosis based on this study must be interpreted with caution and reflects only the natural history of SLE in all our patients (followed up from 1970 until the present) who were diagnosed and treated at our lupus outpatient clinics in the Netherlands.
One of the first studies assessing the prognostic impact of variables like sex, age, and visceral manifestations on mortality was by McCombs and Patterson.15 Figures on disease duration were not given in this study; of the eight men, six had died by the end of the study. They also found that renal involvement was a manifestation with severe prognostic significance; of the 37 patients who died, 27 had renal involvement. In later reports the finding of poorer prognoses among men was confirmed.81 In our prospective study we obtained comparable results. Furthermore, were were able to study other parameters like the influence of age, and the kind and frequency of exacerbations on the disease outcome. Men were older than women at the onset of the disease, yet the duration of the disease between onset and death did not differ significantly between men and women who died during the study. Table 4 shows that in nearly all patients the cause of death was related to the disease course. Only in one of the five male patients was the registered cause of death not related to SLE. Of the 14 patients who died, seven patients were younger and seven were older than 50 years at death. Five patients died in the second to third decade and five in the sixth to seventh decade, suggesting a bimodal mortality curve. The number of patients is very small, however. Owing to the wide age range of the patients who died and the low number of deaths, it was impossible to make a correction for age dependent natural survival rate.
In the earlier reports describing a bimodal pattern it has been suggested that death in the younger patients with SLE is due to. active lupus or intercurrent infection, or both, and in the older patients to cardiovascular disease in the presence of clinically inactive SLE.26 Overall, the death of our patients was most often due to active lupus, which in two cases was complicated by an infection.
In a prospective study by Fessel, of a well-defined population of patients with SLE, a 10 year survival of more than 90% was calculated. 17 Only five deaths occurred among, the 70 patients in whom SLE was newly diagnosed. No data were given concerning the sex, age, or disease symptoms of the patients who died. A major difference in their study is that it concerned a mainly non-Caucasian population. Significantly more serositis and haematological abnormalities have been described in black patients than in white patients with SLE.
In our study the prevalence of renal involvement and neurological or psychiatric symptoms was greater at the onset and at the moment of diagnosis of the disease in the patients who died. Overall, all patients who died showed one or more exacerbations after the diagnosis had been established. In our patient group a cumulative five year and 10 year survival of 94% and 87% could be calculated respectively. Although our figures are comparable with recent results (Table 7) , it must be remembered that our results concern a patient population followed up and treated at the same lupus clinic by the same physicians (AJGS and WB). From studies performed in the past 10 years it can be seen that there has been an overall improvement in prognosis of SLE when compared with earlier studies. Much of this improvement may be due to the treatment, but one must consider the alternative possibility that milder cases are now more often recognised than formerly.
